BPC-157 and KPV Together: What Is Known
BPC-157 and KPV taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
Side by side
Showing 9 of 12 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026 are the same or both unknown.
| Field | BPC-157 | KPV |
|---|---|---|
| Class | Gastric pentadecapeptide | Anti-inflammatory tripeptide |
| Also called | BPC, body protection compound, Pentadecapeptide BPC 157 | Lys-Pro-Val, alpha-MSH fragment |
| Category | Healing & recovery | Healing & recovery |
| FDA status | PCAC voted 8–6 for 503A (Jul 2026) | PCAC voted 8–6 for 503A (Jul 2026) |
| PCAC vote, Jul 2026 | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized |
| WADA | Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition. | WADA status unclearKPV: This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143 | Animal evidence, 2 of 4Strongest: Inflammatory bowel diseases 2008, PMID 18092346 |
| Human studies we summarised | 3 human (0 randomized or controlled) of 25 summarised | 0 human (0 randomized or controlled) of 9 summarised |
| Typical study doses |
| Not reported in study abstractsPubMed search, 11 Oct 2026 |
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 5 mg, 10 mg, 20 mg |
Sold pre-mixed too
Some vials combine these peptides. The blend calculator shows the dose of each component per draw.
BPC-157: a handful of clinic reports, mostly rat work
In a retrospective knee-pain chart review, 11 of the 12 patients who received only BPC-157 reported significant improvement.[17]
The review was retrospective: of 17 patients, 16 were contacted by phone to follow up on their knee pain.[17]
An intravenous pilot in 2 healthy adults reported no adverse effects.[6]
KPV: mouse colitis models and cell work
In mice with chemically induced colitis, KPV treatment led to earlier recovery and better weight regain, and it rescued mice lacking a working melanocortin-1 receptor from death. This is animal data.[9]
Cell experiments suggest KPV enters intestinal and immune cells through the PepT1 transporter, and giving it by mouth reduced colitis in mice.[18]
FDA reports that it has found no human exposure data for any drug product containing KPV.[19]
Tested together? No
A PubMed search on 2 Oct 2026 for BPC-157 with KPV matched 1 record.
Calculated from pubmed query ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]); records matched 1; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
That record's abstract says it examines the proposed uses of these peptides, the concerns raised during the review, and the practical implications for compounders. It is not a study of the combination.[20]
Both peptides were on the July 23 agenda of FDA's advisory committee for the 503A bulks list.[21]
Common questions
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 4Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 5Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 6Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 7Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 8Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 9Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
- 10PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) (132 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab]) (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 16PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine · 2021PMID 34324435Accessed 2 Oct 2026
- 18PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
- 19Official web pageOfficial web page · web page
- 20Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.International journal of pharmaceutical compounding · 2026PMID 42752426Accessed 2 Oct 2026
- 21Official web pageOfficial web page · web page
Found an error? Report a correction.